JAK
Los inhibidores de la Janus quinasa (JAK) son compuestos que se dirigen a la vía de señalización JAK-STAT, la cual está involucrada en el crecimiento celular, la respuesta inmunitaria y la angiogénesis. Al inhibir JAK, estos compuestos pueden reducir la señalización que conduce a la formación de nuevos vasos sanguíneos en los tumores, inhibiendo así el crecimiento tumoral. Los inhibidores de JAK son importantes en el tratamiento del cáncer y las enfermedades inflamatorias. En CymitQuimica, ofrecemos una amplia gama de inhibidores de JAK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 245 productos de "JAK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin AG 490
CAS:Fórmula:C17H14N2O3Pureza:>98.0%(T)(HPLC)Forma y color:White to Light yellow powder to crystalPeso molecular:294.31Ilginatinib hydrochloride
CAS:<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C21H21ClFN7Pureza:99.55%Forma y color:SolidPeso molecular:425.89TAK-901
CAS:<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Fórmula:C28H32N4O3SPureza:99.02% - 99.59%Forma y color:SolidPeso molecular:504.64N-(3-Aminopropyl)cyclohexylamine
CAS:<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Fórmula:C9H20N2Pureza:98.05% - 98.82%Forma y color:Pale Yellow Clear LiquidPeso molecular:156.2685Brepocitinib P-Tosylate
CAS:<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Fórmula:C25H29F2N7O4SPureza:99.82% - 99.97%Forma y color:SolidPeso molecular:561.6WDR5-IN-6
CAS:<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>Fórmula:C13H8Cl2N2O2SPureza:99.69%Forma y color:SoildPeso molecular:327.19Gusacitinib
CAS:<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Fórmula:C24H28N8O2Pureza:98.06% - 99.94%Forma y color:SolidPeso molecular:460.53(E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
CAS:Fórmula:C17H14N2O3Pureza:98%Forma y color:SolidPeso molecular:294.3047Ilginatinib
CAS:<p>Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C21H20FN7Pureza:98.4% - 99.01%Forma y color:SolidPeso molecular:389.43JAK2 Inhibitor V
CAS:<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Fórmula:C23H24N2OPureza:98.36% - 99.15%Forma y color:SolidPeso molecular:344.45Golidocitinib
CAS:<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).</p>Fórmula:C25H31N9O2Pureza:98.87% - 99.88%Forma y color:SolidPeso molecular:489.57Ilginatinib maleate
CAS:<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C25H24FN7O4Pureza:99.74% - 99.82%Forma y color:SolidPeso molecular:505.5Delgocitinib
CAS:<p>Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.</p>Fórmula:C16H18N6OPureza:99.95%Forma y color:SolidPeso molecular:310.35Nimucitinib
CAS:<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>Fórmula:C25H26F2N6O2Pureza:98.71%Forma y color:SoildPeso molecular:480.51HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Fórmula:C60H69N17O11SForma y color:SolidPeso molecular:1236.36JAK2-IN-10
CAS:<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Fórmula:C33H33D3FN9O2Forma y color:SolidPeso molecular:612.71DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Fórmula:C25H38N4O3Forma y color:SolidPeso molecular:442.59Deuruxolitinib
CAS:<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Fórmula:C17H18N6Forma y color:SolidPeso molecular:314.41MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Fórmula:C23H26N4O2SForma y color:SolidPeso molecular:422.54FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidKinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Forma y color:Odour SolidTyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Forma y color:Odour SolidJAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Forma y color:Odour SolidTyk2-IN-22
CAS:<p>Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.</p>Fórmula:C16H16ClN5O2Forma y color:SolidPeso molecular:345.78JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Forma y color:Odour SolidJAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OForma y color:SolidPeso molecular:407.401JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Fórmula:C22H23FN4O3SForma y color:SolidPeso molecular:442.51S-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Fórmula:C17H18N6Pureza:98%Forma y color:SolidPeso molecular:306.37TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Forma y color:SolidPeso molecular:404.16485JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SForma y color:SolidPeso molecular:548.67Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Forma y color:SolidPeso molecular:1514.77SJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Fórmula:C43H45N13O9SPureza:98%Forma y color:SolidPeso molecular:919.96JAK2-IN-6
CAS:<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Fórmula:C14H10ClN3OS2Pureza:99.64%Forma y color:SolidPeso molecular:335.83SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Forma y color:SolidPeso molecular:688.74WDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Fórmula:C29H31F3N4O4Forma y color:SolidPeso molecular:556.576SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Fórmula:C41H46N12O5SForma y color:SolidPeso molecular:818.95Pumecitinib
CAS:<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Fórmula:C17H20N8O2SPureza:99.94%Forma y color:SoildPeso molecular:400.46SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SForma y color:SolidPeso molecular:873.94TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Forma y color:Odour SolidPROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Fórmula:C55H69N13O7SPureza:98%Forma y color:SolidPeso molecular:1056.28AS2553627
CAS:<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Fórmula:C18H19N5OForma y color:SolidPeso molecular:321.38JAK-IN-29
<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>Fórmula:C17H14ClN5O2Pureza:98%Forma y color:SolidPeso molecular:355.78JAK-IN-33
<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>Pureza:98%Forma y color:Odour SolidLH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Fórmula:C29H31F3N6O2SForma y color:SolidPeso molecular:584.66JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Fórmula:C30H32N8O5SForma y color:SolidPeso molecular:616.69JI069
CAS:<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Fórmula:C15H12Cl2N2O4SPureza:98.01%Forma y color:SolidPeso molecular:387.24Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Fórmula:C88H138N20O34P2Pureza:98%Forma y color:SolidPeso molecular:2082.1Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Fórmula:C23H25F5N7O5PPureza:99.57%Forma y color:SolidPeso molecular:605.45JAK-2/3-IN-1
CAS:<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Fórmula:C20H12ClN3OForma y color:SolidPeso molecular:345.79WHI-P180 Hydrochloride
CAS:Fórmula:C16H15N3O3·HClPureza:>97.0%(T)(HPLC)Forma y color:White to Light gray to Light yellow powder to crystalPeso molecular:333.77DTP3
CAS:<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Fórmula:C26H35N7O5Forma y color:SolidPeso molecular:525.6Atinvicitinib
CAS:<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Fórmula:C16H17FN6O3Pureza:99.36%Forma y color:SolidPeso molecular:360.35Itacitinib adipate
CAS:<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Fórmula:C32H33F4N9O5Forma y color:SolidPeso molecular:699.66Ifidancitinib
CAS:<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Fórmula:C20H18FN5O3Pureza:98.05%Forma y color:SolidPeso molecular:395.39WHI-P154
CAS:Fórmula:C16H14BrN3O3Pureza:>98.0%(HPLC)Forma y color:White to Yellow to Orange powder to crystalPeso molecular:376.21CHZ868
CAS:<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Fórmula:C22H19F2N5O2Pureza:99.38%Forma y color:SolidPeso molecular:423.42Ilunocitinib
CAS:<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Fórmula:C17H17N7O2SPureza:99.88%Forma y color:SolidPeso molecular:383.43PF-06651600 malonate
CAS:<p>PF-06651600 is a potent and selective JAK3 inhibitor.</p>Fórmula:C18H23N5O5Forma y color:SolidPeso molecular:389.41Pacritinib
CAS:<p>Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).</p>Fórmula:C28H32N4O3Pureza:99.25% - 99.49%Forma y color:SolidPeso molecular:472.58Filgotinib
CAS:<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Fórmula:C21H23N5O3SPureza:98.03% - ≥95%Forma y color:SolidPeso molecular:425.5Baricitinib phosphate
CAS:<p>Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.</p>Fórmula:C16H20N7O6PSPureza:99.4% - 99.82%Forma y color:SolidPeso molecular:469.41WDR5-0103 hydrochloride[890190-22-4(free base)]
<p>WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:</p>Fórmula:C21H26ClN3O4Pureza:99.66%Forma y color:SolidPeso molecular:419.9Solcitinib
CAS:<p>Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.</p>Fórmula:C22H23N5O2Pureza:99.61% - 99.82%Forma y color:SolidPeso molecular:389.45Fosifidancitinib
CAS:<p>Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.</p>Fórmula:C21H21FN5O7PPureza:99.54%Forma y color:SolidPeso molecular:505.39JAK3-IN-6
CAS:JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nMFórmula:C19H18N4O3Pureza:99.94% - 99.94%Forma y color:SolidPeso molecular:350.37WHI-P97 HCl
<p>WHI-P97 HCl is a potent and selective JAK-3 inhibitor.</p>Fórmula:C16H14Br2ClN3O3Pureza:99.49%Forma y color:SolidPeso molecular:491.56SHR0302
CAS:<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Fórmula:C18H22N8O2SPureza:99.11%Forma y color:SolidPeso molecular:414.48Gusacitinib HCl
CAS:<p>Gusacitinib (ASN-002/EN-3351), a potent SYK/JAK inhibitor, has strong antitumor activity in various cancers.</p>Fórmula:C24H29ClN8O2Forma y color:SolidPeso molecular:497Ritlecitinib
CAS:<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Fórmula:C15H19N5OPureza:98.82% - 99.92%Forma y color:SolidPeso molecular:285.34GLPG0634 analog
CAS:<p>GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.</p>Fórmula:C23H18N6O2Pureza:99.52% - >99.99%Forma y color:SolidPeso molecular:410.43Ruxolitinib
CAS:<p>Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.</p>Fórmula:C17H18N6Pureza:99.4% - >99.99%Forma y color:SolidPeso molecular:306.36Tofacitinib
CAS:<p>Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.</p>Fórmula:C16H20N6OPureza:99% - >99.99%Forma y color:SolidPeso molecular:312.37Itacitinib
CAS:<p>Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.</p>Fórmula:C26H23F4N9OPureza:96.4% - 99.5%Forma y color:SolidPeso molecular:553.51(Z)-LFM-A13
CAS:<p>(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.</p>Fórmula:C11H8Br2N2O2Pureza:99.88%Forma y color:SolidPeso molecular:360Fedratinib
CAS:Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.Fórmula:C27H36N6O3SPureza:97.31% - 99.96%Forma y color:SolidPeso molecular:524.68Ritlecitinib tosylate
CAS:<p>Ritlecitinib (PF-06651600) is a potent, selective JAK3 inhibitor with proven in vivo efficacy, low clearance, and has undergone clinical trials.</p>Fórmula:C22H27N5O4SForma y color:SolidPeso molecular:457.549Ruxolitinib (S enantiomer)
CAS:<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Fórmula:C17H18N6Pureza:99.37% - 99.79%Forma y color:SolidPeso molecular:306.36WHI-P154
CAS:<p>WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.</p>Fórmula:C16H14BrN3O3Pureza:98% - 99.67%Forma y color:SolidPeso molecular:376.2Momelotinib
CAS:<p>Momelotinib (LM-1149), an oral JAK1/2 inhibitor with IC50s 11/18 nM, blocks ATP binding, disrupting JAK-STAT pathway and reducing tumor growth.</p>Fórmula:C23H22N6O2Pureza:97.47% - 99.56%Forma y color:SolidPeso molecular:414.46Ruxolitinib phosphate
CAS:<p>Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.</p>Fórmula:C17H21N6O4PPureza:98% - >99.99%Forma y color:SolidPeso molecular:404.36BD750
CAS:<p>BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in</p>Fórmula:C14H13N3OSPureza:99.02%Forma y color:SolidPeso molecular:271.34Abrocitinib
CAS:<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>Fórmula:C14H21N5O2SPureza:99.09% - 99.91%Forma y color:SolidPeso molecular:323.41Atractylenolide I
CAS:<p>Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.</p>Fórmula:C15H18O2Pureza:97.55% - 99.92%Forma y color:SolidPeso molecular:230.3NVP-BSK805 trihydrochloride
CAS:<p>NVP-BSK805 trihydrochloride inhibits JAK2 (0.48 nM IC50); also affects JAK1, JAK3, TYK2.</p>Fórmula:C27H31Cl3F2N6OForma y color:SolidPeso molecular:599.93Upadacitinib
CAS:<p>Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.</p>Fórmula:C17H19F3N6OPureza:98.96% - 99.94%Forma y color:SolidPeso molecular:380.37AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Fórmula:C19H23N7O2Pureza:99.83% - 99.98%Forma y color:SolidPeso molecular:381.43Pacritinib hydrochloride
CAS:<p>Pacritinib HCl: strong JAK2/Wild-type & JAK2V617F inhibitor (IC50: 23/19 nM), used in AML & MF research.</p>Fórmula:C28H32N4O3·xClHForma y color:SolidRGB-286638 free base
CAS:<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Fórmula:C29H35N7O4Pureza:98% - 99.91%Forma y color:SolidPeso molecular:545.63Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Fórmula:C23H25ClFN7OPureza:99.33% - 99.86%Forma y color:SolidPeso molecular:469.94Oclacitinib
CAS:<p>Oclacitinib (PF-03394197)(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000</p>Fórmula:C15H23N5O2SPureza:98% - 98.45%Forma y color:White To Off-White SolidPeso molecular:337.44Cucurbitacin I
CAS:<p>Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.</p>Fórmula:C30H42O7Pureza:96.69% - 99.8%Forma y color:SolidPeso molecular:514.65Oclacitinib maleate
CAS:<p>Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.</p>Fórmula:C15H23N5O2S·C4H4O4Pureza:99.17%Forma y color:SolidPeso molecular:453.51CEP-33779
CAS:<p>CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.</p>Fórmula:C24H26N6O2SPureza:98.24% - ≥95%Forma y color:SolidPeso molecular:462.57Momelotinib HCl
CAS:<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Fórmula:C23H24Cl2N6O2Forma y color:SolidPeso molecular:487.38Tofacitinib Citrate
CAS:<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Fórmula:C22H28N6O8Pureza:99.19% - 99.75%Forma y color:SolidPeso molecular:504.49JAK-IN-5 hydrochloride
CAS:<p>JAK-IN-5 hydrochloride is a JAK inhibitor [1].</p>Fórmula:C27H32ClFN6OForma y color:SolidPeso molecular:511.03AZD-1480
CAS:<p>AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.</p>Fórmula:C14H14ClFN8Pureza:98.25% - 99.47%Forma y color:SolidPeso molecular:348.77RO8191
CAS:<p>RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.</p>Fórmula:C14H5F6N5OPureza:98% - 98.85%Forma y color:SolidPeso molecular:373.21XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Fórmula:C25H28N6O2Pureza:99.19%Forma y color:SolidPeso molecular:444.532,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Fórmula:C16H13Cl2N3O2Pureza:98.77%Forma y color:SolidPeso molecular:350.2Cerdulatinib
CAS:<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Fórmula:C20H27N7O3SPureza:98.74% - 99.49%Forma y color:SolidPeso molecular:445.54Protosappanin A
CAS:<p>Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.</p>Fórmula:C15H12O5Pureza:99.42% - 99.82%Forma y color:SolidPeso molecular:272.25AMG-47a
CAS:<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Fórmula:C29H28F3N5O2Pureza:98%Forma y color:SolidPeso molecular:535.56Decernotinib
CAS:<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Fórmula:C18H19F3N6OPureza:99.28% - >99.99%Forma y color:SolidPeso molecular:392.38G5-7
CAS:<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Fórmula:C22H19F2NO3Pureza:97.3%Forma y color:SolidPeso molecular:383.39(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Fórmula:C23H24N4OPureza:97.75% - 99.92%Forma y color:SolidPeso molecular:372.46FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Fórmula:C28H32O6Pureza:97% - 97.90%Forma y color:SolidPeso molecular:464.55AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Forma y color:Yellow SolidPeso molecular:294.3GDC-0214
CAS:<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Fórmula:C28H28ClF2N9O3Pureza:99.75%Forma y color:SolidPeso molecular:612.03Baricitinib
CAS:<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Fórmula:C16H17N7O2SPureza:99% - >99.99%Forma y color:SolidPeso molecular:371.42Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Fórmula:C18H22N4O2Pureza:98.67% - 99.4%Forma y color:SolidPeso molecular:326.39Pyridone 6
CAS:<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Fórmula:C18H16FN3OPureza:97.1% - 98.74%Forma y color:SolidPeso molecular:309.34WHI-P97
CAS:<p>WHI-P97 is a rationally designed potent inhibitor of JAK-3.</p>Fórmula:C16H13Br2N3O3Pureza:99.93%Forma y color:SolidPeso molecular:455.1JANEX-1
CAS:<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>Fórmula:C16H15N3O3Pureza:98% - 99.81%Forma y color:SolidPeso molecular:297.31WP1066
CAS:<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Fórmula:C17H14BrN3OPureza:98.92% - 99.73%Forma y color:SolidPeso molecular:356.22Fedratinib hydrochloride hydrate
CAS:<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Fórmula:C27H40Cl2N6O4SPureza:98.96% - 99.87%Forma y color:SolidPeso molecular:615.61AZ960
CAS:<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Fórmula:C18H16F2N6Pureza:96.02% - 98.51%Forma y color:SolidPeso molecular:354.36ZM39923 hydrochloride
CAS:<p>ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.</p>Fórmula:C23H25NO·HClPureza:98.05%Forma y color:SolidPeso molecular:367.91BMS-911543
CAS:<p>BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.</p>Fórmula:C23H28N8OPureza:97.69% - 99.98%Forma y color:SolidPeso molecular:432.52SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Fórmula:C21H18ClFN4O4Pureza:98.99% - 99.77%Forma y color:SolidPeso molecular:444.84FM-381
CAS:<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Fórmula:C24H24N6O2Pureza:98.44%Forma y color:SolidPeso molecular:428.49TG101209
CAS:<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Fórmula:C26H35N7O2SPureza:99% - >99.99%Forma y color:SolidPeso molecular:509.67Deucravacitinib
CAS:Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.Fórmula:C20H19D3N8O3Pureza:98.52% - >99.99%Forma y color:SolidPeso molecular:425.46RO495
CAS:<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Fórmula:C17H14Cl2N6OPureza:97.94%Forma y color:SolidPeso molecular:389.24SC99
CAS:SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.Fórmula:C15H8Cl2FN3OPureza:99.56%Forma y color:SolidPeso molecular:336.15Brevilin A
CAS:<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Fórmula:C20H26O5Pureza:99.97% - >99.99%Forma y color:SolidPeso molecular:346.42Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Fórmula:C20H28ClN7O3SPureza:99.85%Forma y color:SolidPeso molecular:482GS-829845
CAS:<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Fórmula:C17H19N5O2SPureza:99.93%Forma y color:SolidPeso molecular:357.43NVP-BSK805
CAS:<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Fórmula:C27H28F2N6OPureza:98%Forma y color:SolidPeso molecular:490.55Solrikitug
CAS:<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Pureza:95%Forma y color:LiquidZM39923
CAS:<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Fórmula:C23H25NOPureza:98%Forma y color:SolidPeso molecular:331.45(3S,4S)-Tofacitinib
CAS:<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Fórmula:C16H20N6OPureza:98%Forma y color:SolidPeso molecular:312.37SD-1029
CAS:<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>Fórmula:C25H32Br2Cl2N2O3Forma y color:SolidPeso molecular:639.25JAK-IN-11
CAS:<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Fórmula:C23H22FN5O4SPureza:99.75%Forma y color:SolidPeso molecular:483.52JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Forma y color:SolidPeso molecular:515.58JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Fórmula:C19H19ClN2OSForma y color:SolidPeso molecular:358.89Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Forma y color:SolidPeso molecular:362.86TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Fórmula:C21H22N2O2Forma y color:SolidPeso molecular:334.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Fórmula:C19H19N3O4SForma y color:SolidPeso molecular:385.44JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Fórmula:C19H15FN4OPureza:98.27%Forma y color:SolidPeso molecular:334.35TyK2-IN-2
CAS:<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Fórmula:C16H18N6OPureza:98%Forma y color:SolidPeso molecular:310.35JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Fórmula:C27H28F2N6O3Forma y color:SolidPeso molecular:522.55JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Fórmula:C19H19N5O4SForma y color:SolidPeso molecular:413.45Tyk2-IN-5
CAS:<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Fórmula:C21H19FN8O2Pureza:98%Forma y color:SolidPeso molecular:434.43EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Fórmula:C14H24O2Forma y color:SolidPeso molecular:224.34Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Fórmula:C18H15D3N6O3SPureza:98%Forma y color:SolidPeso molecular:401.46MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Fórmula:C21H18N2O3Pureza:98%Forma y color:SolidPeso molecular:346.381,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Fórmula:C6H6Br6Pureza:98%Forma y color:SolidPeso molecular:557.54OICR-0547
CAS:<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Fórmula:C28H29F3N4O4Pureza:98%Forma y color:SolidPeso molecular:542.55INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Fórmula:C19H11Cl2N5Forma y color:SolidPeso molecular:380.23JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Fórmula:C17H23N5O4SForma y color:SolidPeso molecular:393.46TUL01101
CAS:<p>TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.</p>Fórmula:C22H25F2N5O2Forma y color:SolidPeso molecular:429.46CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Forma y color:SolidPeso molecular:303.36GDC-4379
CAS:<p>GDC-4379 is a JAK1 inhibitor that can be used to study asthma.</p>Fórmula:C21H18ClF2N7O3Forma y color:SolidPeso molecular:489.86Peficitinib hydrobromide
CAS:<p>Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.</p>Fórmula:C18H23BrN4O2Forma y color:SolidPeso molecular:407.312Povorcitinib
CAS:<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>Fórmula:C23H22F5N7OForma y color:SolidPeso molecular:507.469(2R,5S)-Ritlecitinib
CAS:<p>(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].</p>Fórmula:C15H19N5OForma y color:SolidPeso molecular:285.34TYK2-IN-11
CAS:<p>TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.</p>Fórmula:C18H17N5O3SForma y color:SolidPeso molecular:383.42Thi-DPPY
CAS:<p>Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.</p>Fórmula:C28H28ClN5O4SForma y color:SolidPeso molecular:566.07PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Fórmula:C18H26N6OForma y color:SolidPeso molecular:342.44SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Fórmula:C24H26N8O3Forma y color:SolidPeso molecular:474.52JAK3-IN-1
CAS:<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Fórmula:C26H30ClN7O2Forma y color:SolidPeso molecular:508.02JAK-IN-10
CAS:<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Fórmula:C20H18FN5O3SPureza:99.53%Forma y color:SolidPeso molecular:427.45JAK-IN-28
CAS:<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>Fórmula:C20H18ClN7OPureza:98%Forma y color:SolidPeso molecular:407.86JAK-IN-30
CAS:<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>Fórmula:C19H26N8SPureza:98%Forma y color:SolidPeso molecular:398.53JAK1-IN-4
CAS:<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>Fórmula:C26H32FN9O2Pureza:98%Forma y color:SolidPeso molecular:521.59JAK3/BTK-IN-2
CAS:<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Fórmula:C25H32N8O2Pureza:99.64% - 99.87%Forma y color:SolidPeso molecular:476.57Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Fórmula:C22H28N6O2Pureza:99.72%Forma y color:SolidPeso molecular:408.5JAK3i
CAS:<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Fórmula:C18H15FN4O3Pureza:98.61% - 99.81%Forma y color:SolidPeso molecular:354.34Jaspamycin
CAS:<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Fórmula:C12H12N4O5Forma y color:SolidPeso molecular:292.25JAK3/BTK-IN-1
CAS:<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Fórmula:C25H28N8OPureza:97.89%Forma y color:SolidPeso molecular:456.54Izencitinib
CAS:<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Fórmula:C22H26N8Pureza:99.82%Forma y color:SolidPeso molecular:402.50STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Fórmula:C15H15ClN4O2Pureza:99.01%Forma y color:SolidPeso molecular:318.76JAK1-IN-8
CAS:<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Fórmula:C22H23FN4O3SPureza:98.4%Forma y color:SolidPeso molecular:442.51JAK-STAT-IN-1
CAS:<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Fórmula:C21H21N5O2Pureza:99.59%Forma y color:SolidPeso molecular:375.42Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Fórmula:C29H32Cl2N2O5SPureza:99.51% - 99.83%Forma y color:SoildPeso molecular:591.55JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Fórmula:C19H17N5O4Pureza:98%Forma y color:SolidPeso molecular:379.37Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Fórmula:C30H37N7O2Forma y color:SolidPeso molecular:527.66Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Fórmula:C21H33F3N6O11Pureza:98%Forma y color:SolidPeso molecular:602.521JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Fórmula:C33H38F2N6O8Forma y color:SolidPeso molecular:684.69TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Fórmula:C27H25F3N4O4Pureza:99.39% - ≥98%Forma y color:SolidPeso molecular:526.51Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Fórmula:C18H21N5O3Pureza:99.85%Forma y color:SolidPeso molecular:355.39JAK kinase-IN-1
CAS:<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Fórmula:C17H19F2N7OSPureza:98%Forma y color:SolidPeso molecular:407.44JAK-IN-5
CAS:<p>JAK-IN-5 is a JAK inhibitor.</p>Fórmula:C27H31FN6OPureza:98.1% - 99.37%Forma y color:SolidPeso molecular:474.57JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Fórmula:C20H24N6O2Pureza:98%Forma y color:SolidPeso molecular:380.44Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Fórmula:C22H20N6O3Forma y color:SolidPeso molecular:416.43FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Fórmula:C25H26N6O2Pureza:98%Forma y color:SolidPeso molecular:442.523JAK2-IN-4
CAS:<p>JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.</p>Fórmula:C23H27N5O4SPureza:98%Forma y color:SolidPeso molecular:469.56TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Fórmula:C17H11ClF2N4O2Forma y color:SolidPeso molecular:376.74Brepocitinib
CAS:<p>Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).</p>Fórmula:C18H21F2N7OPureza:99.82%Forma y color:SolidPeso molecular:389.4ABBV-712
CAS:<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Fórmula:C24H28N4O5Pureza:98%Forma y color:SolidPeso molecular:452.5Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Fórmula:C20H17N9Pureza:98%Forma y color:SolidPeso molecular:383.41JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Fórmula:C20H25N5O2Forma y color:SolidPeso molecular:367.44JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Fórmula:C18H21N4Na2O6PPureza:98%Forma y color:SolidPeso molecular:466.341Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Fórmula:C26H29ClN8OForma y color:SolidPeso molecular:505.01Ginsenoside Rk1
CAS:<p>Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.</p>Fórmula:C42H70O12Pureza:98.46% - 99.13%Forma y color:SolidPeso molecular:767JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Fórmula:C22H24N6O3Pureza:98%Forma y color:SolidPeso molecular:420.46QL-1200186
CAS:<p>QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following</p>Fórmula:C26H27N7O3Pureza:98%Forma y color:SolidPeso molecular:485.54
![WDR5-0103 hydrochloride[890190-22-4(free base)]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT5140.webp&w=3840&q=75)
